Expert Interview
Discussing the 12-week safety and efficacy results from the NORSE EIGHT clinical trial, evaluating Outlook Therapeutics' ophthalmic formulation of bevacizumab, ONS-5010, for the treatment of wet age-related macular degeneration
Ticker(s): OTLKInstitution: Private Practice
- Manages 30 - 40 patients weekly with diabetic macular edema
- Clinical interest in the medical and surgical treatment of diabetic retinopathy, complex retinal detachments, and secondary intraocular lens surgery
- Authored numerous articles in peer-reviewed journals as well as a textbook highlighting retinal genetic diseases.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
